Edition:
United Kingdom

People: Alliqua BioMedical Inc (ALQA.OQ)

ALQA.OQ on NASDAQ Stock Exchange Capital Market

2.30USD
21 Sep 2018
Change (% chg)

$-0.10 (-4.17%)
Prev Close
$2.40
Open
$2.40
Day's High
$2.41
Day's Low
$2.25
Volume
3,796
Avg. Vol
3,976
52-wk High
$4.50
52-wk Low
$1.59

Johnson, David 

Mr. David Ian Johnson is President, Chief Executive officer and Director of Alliqua Biomedical,Inc. on February 4, 2013. He was appointed our President and Chief Executive officer on February 4, 2013. Mr. Johnson was formerly President of the ConvaTec Division of Bristol-Myers Squibb, Inc. until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.’s manufacturing and infrastructure into Europe. From 2008 through 2012, Mr. Johnson served as the Chief Executive Officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.’s board of directors and the board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an Undergraduate Business Degree in Marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of the University of Pennsylvania. We believe that Mr. Johnson’s extensive experience in the pharmaceutical and biotechnology fields, as well as his executive leadership experience, make him an asset that will serve as a bridge between our board of directors and our executive officers.

Basic Compensation

Total Annual Compensation, USD 595,000
Restricted Stock Award, USD 258,000
Long-Term Incentive Plans, USD --
All Other, USD 11,400
Fiscal Year Total, USD 864,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --